Effects of HER Family–targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast CancerDenis M. Collins, John Crown|Clinical Cancer Research|2020Cited by 75
Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancerDenis M. Collins, Birgit Bossenmaier|PLoS ONE|2017Cited by 54
Alterations in immune cell phenotype and cytotoxic capacity in HER2+ breast cancer patients receiving HER2-targeted neo-adjuvant therapyNicola Gaynor, Denis M. Collins|British Journal of Cancer|2023Cited by 12